• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

UB-612 疫苗加强针后，针对严重急性呼吸综合征冠状病毒 2 奥密克戎 BA.1 和 BA.2 的高中和抗体水平。

High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster.

机构信息

Vaxxinity Inc, Dallas, Texas, USA.

United Biomedical Inc Asia, Hsinchu, Taiwan.

出版信息

J Infect Dis. 2022 Oct 17;226(8):1401-1406. doi: 10.1093/infdis/jiac241.

DOI:10.1093/infdis/jiac241
PMID:35723969
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9278180/
Abstract

The highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has caused high rates of breakthrough infections in those previously vaccinated with ancestral strain coronavirus disease 2019 (COVID-19) vaccines. Here, we demonstrate that a booster dose of UB-612 vaccine candidate delivered 7-9 months after primary vaccination increased neutralizing antibody levels by 131-, 61-, and 49-fold against ancestral SARS-CoV-2 and the Omicron BA.1 and BA.2 variants, respectively. Based on the receptor-binding domain protein binding antibody responses, the UB-612 third-dose booster may lead to an estimated approximately 95% efficacy against symptomatic COVID-19 caused by the ancestral strain. Our results support UB-612 as a potential potent booster against current and emerging SARS-CoV-2 variants.

摘要

高度传染性的严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）奥密克戎变体导致先前接种过原始株冠状病毒病 2019（COVID-19）疫苗的人突破性感染率很高。在这里，我们证明，在初次接种疫苗后 7-9 个月接种 UB-612 候选疫苗加强针，分别使针对原始 SARS-CoV-2 以及奥密克戎 BA.1 和 BA.2 变体的中和抗体水平提高了 131 倍、61 倍和 49 倍。基于受体结合域蛋白结合抗体反应，UB-612 第三剂加强针可能使针对由原始株引起的有症状 COVID-19 的估计有效率达到约 95%。我们的结果支持 UB-612 作为针对当前和新兴 SARS-CoV-2 变体的潜在有效加强针。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ea6/9574663/60a0959e3efd/jiac241f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ea6/9574663/8f038eb3dffc/jiac241f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ea6/9574663/60a0959e3efd/jiac241f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ea6/9574663/8f038eb3dffc/jiac241f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ea6/9574663/60a0959e3efd/jiac241f2.jpg

相似文献

1
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster.UB-612 疫苗加强针后，针对严重急性呼吸综合征冠状病毒 2 奥密克戎 BA.1 和 BA.2 的高中和抗体水平。
J Infect Dis. 2022 Oct 17;226(8):1401-1406. doi: 10.1093/infdis/jiac241.
2
Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.先前感染和未感染个体接种奥密克戎二价加强针后针对原始 SARS-CoV-2 和奥密克戎 BA.5 的中和抗体和 T 细胞应答。
J Med Virol. 2023 Aug;95(8):e28989. doi: 10.1002/jmv.28989.
3
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.两剂蛋白亚单位疫苗 MVC-COV1901 初免后加强接种多剂 mRNA 疫苗可增强针对新型 SARS-CoV-2 变异株的体液和细胞免疫应答。
Microbiol Spectr. 2022 Oct 26;10(5):e0060922. doi: 10.1128/spectrum.00609-22. Epub 2022 Aug 25.
4
Increased antibody titers but induced T cell AICD and apoptosis response in COVID-19 convalescents by inactivated vaccine booster.新冠灭活疫苗加强针可诱导恢复期患者抗体滴度升高，并引起 T 细胞免疫自稳失衡和凋亡。
Microbiol Spectr. 2024 Mar 5;12(3):e0243523. doi: 10.1128/spectrum.02435-23. Epub 2024 Feb 6.
5
SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.养老院居民接种二价 COVID-19 疫苗后对原始 SARS-CoV-2 株和奥密克戎 BA.1 和 BA.4/BA.5 变异株的 SARS-CoV-2 抗体反应 - 俄亥俄州和罗得岛，2022 年 9 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2023 Jan 27;72(4):100-106. doi: 10.15585/mmwr.mm7204a4.
6
Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.与注射用和雾化用 Ad5-nCoV 加强针和 BA.2 感染相关的中和抗体水平。
BMC Med. 2023 Jul 3;21(1):233. doi: 10.1186/s12916-023-02942-3.
7
A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants.鼻喷奥密克戎疫苗加强针引发针对新型 SARS-CoV-2 变异株的强烈中和抗体应答。
Emerg Microbes Infect. 2022 Dec;11(1):964-967. doi: 10.1080/22221751.2022.2053365.
8
Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents.加强针后针对 SARS-CoV-2 奥密克戎变异株的中和抗体效力和对野生型恢复期患者的两年纵向抗体研究。
Int Immunopharmacol. 2023 Jun;119:110151. doi: 10.1016/j.intimp.2023.110151. Epub 2023 Apr 5.
9
A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.第四针奥密克戎 RBD 疫苗加强了对 vaccinated mice 中 SARS-CoV-2 变异株（包括 BA.1 和 BA.2）的广泛中和作用。
J Med Virol. 2022 Aug;94(8):3992-3997. doi: 10.1002/jmv.27811. Epub 2022 May 6.
10
Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.暴露于 BA.4/5 蛋白可导致疫苗接种者体内对奥密克戎 BA.1、BA.2、BA.2.12.1 和 BA.4/5 的中和作用。
Sci Immunol. 2022 Dec 23;7(78):eade9888. doi: 10.1126/sciimmunol.ade9888.

引用本文的文献

1
Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial.用mRNA、腺病毒或灭活新冠疫苗进行初免的成年人中UB-612异源加强针的安全性和免疫原性：一项随机、活性对照的3期试验。
EClinicalMedicine. 2025 Jul 21;86:103349. doi: 10.1016/j.eclinm.2025.103349. eCollection 2025 Aug.
2
COVID-19 Vaccines: Where Did We Stand at the End of 2023?COVID-19 疫苗：2023 年底我们处于什么位置？
Viruses. 2024 Jan 29;16(2):203. doi: 10.3390/v16020203.
3
RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques.

本文引用的文献

1
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost.接种 SARS-CoV-2 mRNA 加强针后，记忆 B 细胞的效力和广度增加。
Nature. 2022 Jul;607(7917):128-134. doi: 10.1038/s41586-022-04778-y. Epub 2022 Apr 21.
2
Vaccine protection against the SARS-CoV-2 Omicron variant in macaques.疫苗对猕猴体内 SARS-CoV-2 奥密克戎变异株的保护作用。
Cell. 2022 Apr 28;185(9):1549-1555.e11. doi: 10.1016/j.cell.2022.03.024. Epub 2022 Mar 17.
3
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants.
RBD蛋白/肽疫苗UB-612在食蟹猴中引发针对SARS-CoV-2的黏膜和Fc介导的抗体反应。
Vaccines (Basel). 2023 Dec 29;12(1):40. doi: 10.3390/vaccines12010040.
4
Beta-spike-containing boosters induce robust and functional antibody responses to SARS-CoV-2 in macaques primed with distinct vaccines.含 Beta 棘突蛋白的加强针在以不同疫苗为基础免疫的猕猴中诱导针对 SARS-CoV-2 的强大且有功能的抗体反应。
Cell Rep. 2023 Nov 28;42(11):113292. doi: 10.1016/j.celrep.2023.113292. Epub 2023 Oct 28.
5
Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate.新型多价 SARS-CoV-2/COVID-19 疫苗候选物的免疫原性和疗效。
Front Immunol. 2023 Jun 19;14:1160065. doi: 10.3389/fimmu.2023.1160065. eCollection 2023.
6
Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines.基于 SARS-CoV-2 受体结合域的 COVID-19 疫苗的进展。
Expert Rev Vaccines. 2023 Jan-Dec;22(1):422-439. doi: 10.1080/14760584.2023.2211153.
7
Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses.针对刺突蛋白和非刺突蛋白上保守表位的泛 SARS-CoV-2 疫苗，以诱导有效、广谱和持久的免疫应答。
PLoS Pathog. 2023 Apr 20;19(4):e1010870. doi: 10.1371/journal.ppat.1010870. eCollection 2023 Apr.
8
How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020-2022.2020-2022 年台湾地区应对 COVID-19 疫情的措施和 COVID-19 疫情对台湾地区的影响。
J Microbiol Immunol Infect. 2023 Jun;56(3):433-441. doi: 10.1016/j.jmii.2023.04.001. Epub 2023 Apr 6.
9
Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern.开发针对 SARS-CoV-2 及其关注变种的新一代疫苗。
Viruses. 2023 Feb 24;15(3):624. doi: 10.3390/v15030624.
10
A Synthetic SARS-CoV-2-Derived T-Cell and B-Cell Peptide Cocktail Elicits Full Protection against Lethal Omicron BA.1 Infection in H11-K18-hACE2 Mice.一种合成的源自严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的T细胞和B细胞肽混合物可对H11-K18-hACE2小鼠的致死性奥密克戎BA.1感染提供完全保护。
Microbiol Spectr. 2023 Mar 13;11(2):e0419422. doi: 10.1128/spectrum.04194-22.
一种多表位 SARS-CoV-2 疫苗可提供针对 Delta 和奥密克戎变异株的持久 B 细胞和 T 细胞免疫。
J Clin Invest. 2022 May 16;132(10). doi: 10.1172/JCI157707.
4
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎（B.1.1.529）变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
5
Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition.恢复期 COVID-19 患者对 SARS-CoV-2 的中和抗体反应具有变异性，与疾病严重程度和受体结合域识别相关。
Front Immunol. 2022 Jan 31;13:830710. doi: 10.3389/fimmu.2022.830710. eCollection 2022.
6
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.mRNA-1273加强疫苗接种后对SARS-CoV-2奥密克戎变体的中和作用。
N Engl J Med. 2022 Mar 17;386(11):1088-1091. doi: 10.1056/NEJMc2119912. Epub 2022 Jan 26.
7
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.接种异源科兴疫苗加辉瑞-BioNTech 加强针后对 SARS-CoV-2 德尔塔和奥密克戎变异株的中和抗体。
Nat Med. 2022 Mar;28(3):481-485. doi: 10.1038/s41591-022-01705-6. Epub 2022 Jan 20.
8
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa.南非 SARS-CoV-2 奥密克戎变异株的快速流行扩张。
Nature. 2022 Mar;603(7902):679-686. doi: 10.1038/s41586-022-04411-y. Epub 2022 Jan 7.
9
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.由 BNT162b2 mRNA 疫苗诱导的人血清对 SARS-CoV-2 奥密克戎的中和作用。
Science. 2022 Feb 11;375(6581):678-680. doi: 10.1126/science.abn7591. Epub 2022 Jan 18.
10
Towards a population-based threshold of protection for COVID-19 vaccines.针对 COVID-19 疫苗的基于人群的保护阈值。
Vaccine. 2022 Jan 21;40(2):306-315. doi: 10.1016/j.vaccine.2021.12.006. Epub 2021 Dec 15.